1. Home
  2. SLVM vs OMER Comparison

SLVM vs OMER Comparison

Compare SLVM & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sylvamo Corporation

SLVM

Sylvamo Corporation

N/A

Current Price

$38.64

Market Cap

1.3B

ML Signal

N/A

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$17.50

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SLVM
OMER
Founded
1898
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
SLVM
OMER
Price
$38.64
$17.50
Analyst Decision
Buy
Buy
Analyst Count
3
3
Target Price
★ $46.00
$27.50
AVG Volume (30 Days)
338.4K
★ 1.0M
Earning Date
11-06-2026
11-16-2026
Dividend Yield
★ 4.67%
N/A
EPS Growth
N/A
★ 98.15
EPS
N/A
★ 0.77
Revenue
★ $3,351,000,000.00
$29,868,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$73.59
P/E Ratio
★ N/A
$23.42
Revenue Growth
★ N/A
N/A
52 Week Low
$30.40
$6.70
52 Week High
$56.80
$21.24

Technical Indicators

Market Signals
Indicator
SLVM
OMER
Relative Strength Index (RSI) 64.80 48.07
Support Level $36.32 $16.33
Resistance Level $40.94 $19.68
Average True Range (ATR) 1.67 0.95
MACD 0.74 0.04
Stochastic Oscillator 74.06 42.53

Price Performance

Historical Comparison
SLVM
OMER

About SLVM Sylvamo Corporation

Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: